Human CD23/Fc epsilon RII Antibody Summary
Accession # P06734
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
CD23/Fc epsilon RII in Human PBMCs. CD23/Fce RII was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using 10 µg/mL Goat Anti-Human CD23/Fce RII Antigen Affinity-purified Polyclonal Antibody (Catalog # AF123) for 3 hours at room temperature. Cells were stained with the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD23/Fc epsilon RII
CD23 (also named B cell differentiation antigen) is a member of subgroup II of the C-type (Ca++-dependent) lectin superfamily (1-5). Human CD23 is a 47 kDa, type II transmembrane glycoprotein that is expressed by a wide variety of cell types (6-10). The full-length receptor is 321 amino acids (aa) in length and contains a 274 aa extracellular region, a 26 aa transmembrane segment, and a 21 aa cytoplasmic domain. The extracellular region contains a C-type lectin domain and a connecting stalk with coiled-coil topography (3, 11). The lectin domain binds both protein and carbohydrate in an apparently Ca++ independent manner (11). The coiled-coil region contributes to oligomerization (11, 12). The lectin domain in human CD23 (aa 162-284) shares 64%, 62%, and 68% aa sequence identity with the lectin domains in mouse, rat, and bovine CD23, respectively. In the cytoplasmic region, two FC isoforms exist which arise from alternate start sites (6, 12). The “a” (or long) isoform begins with the sequence MEEGQYS and is constitutively expressed by B cells. It is believed to participate in IgE-mediated endocytosis (13). The “b” (or short) isoform begins with MNPPSQ and is induced on a wide variety of cell types by IL-4 (6). Fcb reportedly contributes to IgE-mediated phagocytosis (13). Fcb expressing cells include eosinophils, monocytes, visceral smooth muscle and intestinal epithelium (6, 14, 15). At least four soluble forms of CD23 are known to exist. They range in molecular weight from 25 kDa to 37 kDa, with the 25 kDa form predominating in sera (16). Soluble CD23 (sFc) is generated by metalloprotease (ADAM8; ADAM15; ADAM28) and cysteine-protease activity (16-18). Cleavage usually occurs between aa 150-160 (7, 8). It is unclear if sequential metalloprotease-cysteine protease activity is necessary for the generation of all soluble forms. Both soluble and membrane-bound CD23 show bioactivity. Ligands for CD23 include CD21, IgE, CD11b, and CD11c (19-21). CD23 binding to CD11b and Cd11c on monocytes results in oxidative product generation and proinflammatory cytokine release (21). On B cells, sCD23 induces IgE secretion by binding CD21. Conversely, secreted IgE will, in turn, bind B cell membrane CD23, rendering it unavailable for cleavage, and thus shutting down IgE production (11).
- Kijimoto-Ochiai, S. (2002) Cell. Mol. Life Sci. 59:648.
- Heyman, B. (2000) Annu. Rev. Immunol. 18:709.
- Bajorath, J. and A. Aruffo (1996) Protein Sci. 5:240.
- Drickamer, K. (1993) Curr. Opin. Struct. Biol. 3:393.
- Drickamer, K. (1999) Curr. Opin. Struct. Biol. 9:585.
- Yokota, A. et al. (1988) Cell 55:611.
- Ludin, C. et al. (1987) EMBO J. 6:109.
- Ikuta, K. et al. (1987) Proc. Natl. Acad. Sci. USA 84:819.
- Kikutani, H. et al. (1986) Cell 47:657.
- Letellier, M. et al. (1988) J. Immunol. 141:2374.
- Hibbert, R.G. et al. (2005) J. Exp. Med. 202:751.
- Beavuil, A.J. et al. (1992) Proc. Natl. Acad. Sci. USA 89:753.
- Yokota, A. et al. (1992) Proc. Natl. Acad. Sci. USA 89:5030.
- Belleau, J.T. et al. (2005) Clin. Mol. Allergy 3:6.
- Tu, Y. et al. (2005) Gastroenterology 129:928.
- Marolewski, A.E. et al. (1998) Biochem. J. 333:573.
- Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
- Karagiannis, S.N. et al. (2001) Immunology 103:319.
- Aubry, J-P. et al. (1992) Nature 358:505.
- Sarfati, M. and G. Delespeese (1988) J. Immunol. 141:2195.
- Lecoanet-Henchoz, S. et al. (1995) Immunity 3:119.
Citations for Human CD23/Fc epsilon RII Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.
Authors: Cui X, Zhang L, Magli A, Catera R, Yan X, Griffin D, Rothstein T, Barrientos J, Kolitz J, Allen S, Rai K, Chiorazzi N, Chu C
Sample Types: Whole Cells
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.
Authors: Arruga F, Gizdic B, Serra S, Vaisitti T, Ciardullo C, Coscia M, Laurenti L, D'Arena G, Jaksic O, Inghirami G, Rossi D, Gaidano G, Deaglio S
Sample Types: Whole Tissue
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Cell and Tissue Staining Kits
Reviews for Human CD23/Fc epsilon RII Antibody
There are currently no reviews for this product. Be the first to review Human CD23/Fc epsilon RII Antibody and earn rewards!
Have you used Human CD23/Fc epsilon RII Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image